Skip to content
Evigrade
MajorDirect oral anticoagulants (factor Xa inhibitors)×Macrolide antibiotic

Updated · Methodology

Mechanism

Erythromycin moderately inhibits the transporter P-glycoprotein (P-gp) and the enzyme CYP3A4 (erythromycin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Edoxaban is a P-gp substrate (edoxaban SmPC, European Medicines Agency, EMA). Erythromycin 500 mg four times daily for 8 days increased the edoxaban area under the concentration–time curve (AUC) by 85% and its peak concentration by 68% (edoxaban SmPC, EMA). The Spanish erythromycin SmPCs report a stronger effect of oral anticoagulants, such as warfarin and rivaroxaban, taken with erythromycin (erythromycin SmPC, AEMPS). According to the erythromycin label of the US Food and Drug Administration (FDA), this effect may be more pronounced in older people.

Symptoms

The main risk is bleeding. It can occur at any site and can be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Gastrointestinal bleeding, vaginal bleeding and bleeding into the skin are common. Intracranial bleeding is uncommon, and menstrual bleeding may become heavier or last longer (edoxaban SmPC, EMA). Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause. An unexplained fall in haemoglobin or blood pressure points to hidden bleeding (edoxaban SmPC, EMA).

Management

With erythromycin, the recommended edoxaban dose is 30 mg once daily instead of the usual 60 mg (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The European Heart Rhythm Association table gives the same dose for this pair (EHRA 2021). Several reasons for reduction do not lower the dose further. With creatinine clearance of 15–50 mL/min or body weight of 60 kg or less as well, it stays at 30 mg (edoxaban SmPC, EMA). In the edoxaban SmPC, the 30 mg dose applies while the two drugs are taken together. The US label describes the edoxaban trial in deep vein thrombosis and pulmonary embolism. There, patients took 30 mg during a short course of erythromycin. They went back to 60 mg as soon as they stopped erythromycin, unless there was another reason for a lower dose (edoxaban label, US Food and Drug Administration, FDA). Oral anticoagulants may act more strongly with erythromycin (erythromycin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), especially in older people (erythromycin label, FDA). Promptly evaluate any signs of blood loss (edoxaban label, FDA). Haemoglobin and haematocrit may help detect hidden bleeding. Stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA). There is no specific antidote. For life-threatening bleeding that cannot be controlled, the SmPC describes a 4-factor prothrombin complex concentrate at 50 IU/kg. It reversed the effects of edoxaban 30 minutes after the end of the infusion (edoxaban SmPC, EMA). In the USA, the edoxaban dose for atrial fibrillation is not reduced because of P-glycoprotein (P-gp) inhibitors (edoxaban label, FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Edoxaban

Other interactions with Erythromycin